Curcumin inhibits proliferation of hepatocellular carcinoma cells by blocking PTPN1 and PTPN11 expression

Zhang,Jingru; Liu,Yang; Wang,Xiaojie; Wang,Zhiyi; Xing,Enjia; Li,Jingmin; Wang,Dong

doi:10.3892/ol.2023.13893

Curcumin inhibits proliferation of hepatocellular carcinoma cells by blocking PTPN1 and PTPN11 expression

Authors:
- Jingru Zhang
- Yang Liu
- Xiaojie Wang
- Zhiyi Wang
- Enjia Xing
- Jingmin Li
- Dong Wang
View Affiliations

Affiliations: Department of Histology and Embryology, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Quality Department, Shandong Runzhong Pharmaceutical Co., Ltd., Yantai, Shandong 264003, P.R. China, Department of Human Anatomy, Binzhou Medical University, Yantai, Shandong 264003, P.R. China
Published online on: June 1, 2023 https://doi.org/10.3892/ol.2023.13893
Article Number: 307
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The antitumor mechanism of curcumin is unclear, especially in hepatocellular carcinoma (HCC) cells. To clarify the mechanism of action of curcumin in the effective treatment of HCC, the targets of curcumin were screened and validated. Candidate genes of curcumin for HCC were screened using the traditional Chinese medicine systems pharmacology (TCMSP) database and validated using The Cancer Genome Atlas (TCGA) database. The correlation of mRNA expression levels between key candidate genes was identified in the TCGA liver hepatocellular carcinoma (LIHC) dataset. The effects on prognosis were analyzed to identify the target gene of curcumin, which inhibits HCC cell proliferation. Based on the subcutaneous xenograft model of human HCC in nude mice, the expression levels of target proteins were observed using immunohistochemistry. The analysis results of the present study identified the target genes of curcumin, which were obtained by screening the TCSMP database. The protein tyrosine phosphatase non‑receptor type 1 (PTPN1) was obtained from TCGA database analysis of the targeted genes. The expression levels of PTPN1 and its homologous sequence genes in TCGA LIHC project was analyzed to identify the potential target gene of curcumin, for use in HCC treatment. Next, xenograft experiments were performed to investigate the therapeutic effects of curcumin in an animal model. Curcumin was demonstrated to inhibit the growth of HCC xenograft tumors in mice. Immunohistochemistry results demonstrated that the protein expression levels of PTPN1 and PTPN11 in the curcumin group were significantly lower compared with those in the control group. In conclusion, these results demonstrated that curcumin inhibits the proliferation of HCC cells by inhibiting the expression of PTPN1 and PTPN11.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021. View Article : Google Scholar : PubMed/NCBI
2	Forner A, Reig M and Bruix J: Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
3	Luo XY, Wu KM and He XX: Advances in drug development for hepatocellular carcinoma: Clinical trials and potential therapeutic targets. J Exp Clin Cancer Res. 40:1722021. View Article : Google Scholar : PubMed/NCBI
4	Zhang HH, Zhang Y, Cheng YN, Gong FL, Cao ZQ, Yu LG and Guo XL: Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog. 57:44–56. 2018. View Article : Google Scholar : PubMed/NCBI
5	Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS and Nath LR: Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem. 45:e137612021. View Article : Google Scholar : PubMed/NCBI
6	Ghobadi N and Asoodeh A: Co-administration of curcumin with other phytochemicals improves anticancer activity by regulating multiple molecular targets. Phytother Res. 37:1688–1702. 2023. View Article : Google Scholar : PubMed/NCBI
7	Khan H, Ni Z, Feng H, Xing Y, Wu X, Huang D, Chen L, Niu Y and Shi G: Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2)-lncRNA H19 to silence Wnt/β-catenin signaling. Phytomedicine. 91:1537062021. View Article : Google Scholar : PubMed/NCBI
8	Bai C, Zhao J, Su J, Chen J, Cui X, Sun M and Zhang X: Curcumin induces mitochondrial apoptosis in human hepatoma cells through BCLAF1-mediated modulation of PI3K/AKT/GSK-3β signaling. Life Sci. 306:1208042022. View Article : Google Scholar : PubMed/NCBI
9	Khan H, Ullah H and Nabavi SM: Mechanistic insights of hepatoprotective effects of curcumin: Therapeutic updates and future prospects. Food Chem Toxicol. 124:182–191. 2019. View Article : Google Scholar : PubMed/NCBI
10	Xu J, Lin H, Wu G, Zhu M and Li M: IL-6/STAT3 is a promising therapeutic target for hepatocellular carcinoma. Front Oncol. 11:7609712021. View Article : Google Scholar : PubMed/NCBI
11	Shao S, Duan W, Xu Q, Li X, Han L, Li W, Zhang D, Wang Z and Lei J: Curcumin suppresses hepatic stellate cell-induced hepatocarcinoma angiogenesis and invasion through downregulating CTGF. Oxid Med Cell Longev. 2019:81485102019. View Article : Google Scholar : PubMed/NCBI
12	Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, et al: An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. 173:400–416.e11. 2018. View Article : Google Scholar : PubMed/NCBI
13	Yu G, Wang LG, Han Y and He QY: clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
14	Sreepriya M and Bali G: Chemopreventive effects of embelin and curcumin against N-nitrosodiethylamine/phenobarbital-induced hepatocarcinogenesis in Wistar rats. Fitoterapia. 76:549–555. 2005. View Article : Google Scholar : PubMed/NCBI
15	Karaboga Arslan A, Uzunhisarcıklı E, Yerer M and Bishayee A: The golden spice curcumin in cancer: A perspective on finalized clinical trials during the last 10 years. J Cancer Res Ther. 18:19–26. 2022. View Article : Google Scholar : PubMed/NCBI
16	Wang L, Zhu Z, Han L, Zhao L, Weng J, Yang H, Wu S, Chen K, Wu L and Chen T: A curcumin derivative, WZ35, suppresses hepatocellular cancer cell growth via downregulating YAP-mediated autophagy. Food Funct. 10:3748–3757. 2019. View Article : Google Scholar : PubMed/NCBI
17	Giordano A and Tommonaro G: Curcumin and cancer. Nutrients. 11:23762019. View Article : Google Scholar : PubMed/NCBI
18	Elkhamesy A, Refaat M, Gouida MSO, Alrdahe SS and Youssef MM: Diminished CCl₄-induced hepatocellular carcinoma, oxidative stress, and apoptosis by co-administration of curcumin or selenium in mice. J Food Biochem. 46:e138452022. View Article : Google Scholar : PubMed/NCBI
19	Salehi B, Stojanović-Radić Z, Matejić J, Sharifi-Rad M, Anil Kumar NV, Martins N and Sharifi-Rad J: The therapeutic potential of curcumin: A review of clinical trials. Eur J Med Chem. 163:527–545. 2019. View Article : Google Scholar : PubMed/NCBI
20	Tonks NK, Diltz CD and Fischer EH: Purification of the major protein-tyrosine-phosphatases of human placenta. J Biol Chem. 263:6722–6730. 1988. View Article : Google Scholar : PubMed/NCBI
21	Chen PJ and Zhang YT: Protein tyrosine phosphatase 1B (PTP1B): Insights into its new implications in tumorigenesis. Curr Cancer Drug Targets. 22:181–194. 2022. View Article : Google Scholar : PubMed/NCBI
22	Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T and Peethambaran B: Protein tyrosine phosphatases: Mechanisms in cancer. Int J Mol Sci. 22:128652021. View Article : Google Scholar : PubMed/NCBI
23	Teimouri M, Hosseini H, ArabSadeghabadi Z, Babaei-Khorzoughi R, Gorgani-Firuzjaee S and Meshkani R: The role of protein tyrosine phosphatase 1B (PTP1B) in the pathogenesis of type 2 diabetes mellitus and its complications. J Physiol Biochem. 78:307–322. 2022. View Article : Google Scholar : PubMed/NCBI
24	Maheshwari N, Karthikeyan C, Trivedi P and Moorthy NSHN: Recent advances in protein tyrosine phosphatase 1B targeted drug discovery for type II diabetes and obesity. Curr Drug Targets. 19:551–575. 2018. View Article : Google Scholar : PubMed/NCBI
25	Kostrzewa T, Przychodzen P, Gorska-Ponikowska M and Kuban-Jankowska A: Curcumin and Cinnamaldehyde as PTP1B inhibitors with antidiabetic and anticancer potential. Anticancer Res. 39:745–749. 2019. View Article : Google Scholar : PubMed/NCBI
26	Kostrzewa T, Wołosewicz K, Jamrozik M, Drzeżdżon J, Siemińska J, Jacewicz D, Górska-Ponikowska M, Kołaczkowski M, Łaźny R and Kuban-Jankowska A: Curcumin and its new derivatives: Correlation between cytotoxicity against breast cancer cell lines, degradation of PTP1B phosphatase and ROS generation. Int J Mol Sci. 22:103682021. View Article : Google Scholar : PubMed/NCBI
27	Radhakrishnan VM, Kojs P, Young G, Ramalingam R, Jagadish B, Mash EA, Martinez JD, Ghishan FK and Kiela PR: pTyr421 cortactin is overexpressed in colon cancer and is dephosphorylated by curcumin: Involvement of non-receptor type 1 protein tyrosine phosphatase (PTPN1). PLoS One. 9:e857962014. View Article : Google Scholar : PubMed/NCBI
28	Chen C, Cao M, Zhu S, Wang C, Liang F, Yan L and Luo D: Discovery of a novel inhibitor of the protein tyrosine phosphatase Shp2. Sci Rep. 5:176262015. View Article : Google Scholar : PubMed/NCBI
29	Asmamaw MD, Shi XJ, Zhang LR and Liu HM: A comprehensive review of SHP2 and its role in cancer. Cell Oncol (Dordr). 45:729–753. 2022. View Article : Google Scholar : PubMed/NCBI
30	Liu JJ, Li Y, Chen WS, Liang Y, Wang G, Zong M, Kaneko K, Xu R, Karin M and Feng GS: Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-catenin, PIK3CA and MET. J Hepatol. 69:79–88. 2018. View Article : Google Scholar : PubMed/NCBI
31	Han T, Xiang DM, Sun W, Liu N, Sun HL, Wen W, Shen WF, Wang RY, Chen C, Wang X, et al: PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 63:651–660. 2015. View Article : Google Scholar : PubMed/NCBI
32	Yue X, Han T, Hao W, Wang M and Fu Y: SHP2 knockdown ameliorates liver insulin resistance by activating IRS-2 phosphorylation through the AKT and ERK1/2 signaling pathways. FEBS Open Bio. 10:2578–2587. 2020. View Article : Google Scholar : PubMed/NCBI
33	Xiang D, Cheng Z, Liu H, Wang X, Han T, Sun W, Li X, Yang W, Chen C, Xia M, et al: Shp2 promotes liver cancer stem cell expansion by augmenting β-catenin signaling and predicts chemotherapeutic response of patients. Hepatology. 65:1566–1580. 2017. View Article : Google Scholar : PubMed/NCBI